AP NEWS

Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Pipeline Review, H2 2018 - ResearchAndMarkets.com

September 19, 2018

DUBLIN--(BUSINESS WIRE)--Sep 19, 2018--The “Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Pipeline Review, H2 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Glucose Dependent Insulinotropic Receptor pipeline Target constitutes close to 14 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes.The report outlays comprehensive information on the Glucose Dependent Insulinotropic Receptor targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

The molecules developed by companies in Phase I, Preclinical and Discovery stages are 3, 8 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. The report covers products from therapy areas Metabolic Disorders, Undisclosed and Respiratory which include indications Type 2 Diabetes, Obesity, Unspecified and Asthma.

Furthermore, this report also reviews key players involved in Glucose Dependent Insulinotropic Receptor targeted therapeutics development with respective active and dormant or discontinued projects.

Companies FeaturedAmgen Inc.Arena Pharmaceuticals Inc.CymaBay Therapeutics Inc.Dong-A Socio Holdings Co Ltd.Hyundai Pharmaceutical Co Ltd.Japan Tobacco Inc.Kowa Co Ltd.Merck & Co Inc.Novartis AGTaisho Pharmaceutical Holdings Co Ltd.Yuhan Corp.

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/987bx5/glucose_dependent?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180919005365/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Proteomics,Endocrine and Metabolic Disorders Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/19/2018 07:33 AM/DISC: 09/19/2018 07:33 AM

http://www.businesswire.com/news/home/20180919005365/en

AP RADIO
Update hourly